New wearable patch for remote monitoring of chronic wounds

New wearable patch for remote monitoring of chronic wounds

Research could be starting point for wound dressings with 'built-in infection stoppers' Chronic wounds can take months or even years to heal. In 20 per cent of the cases, the injury never heals and can lead to a limb amputation. This dramatic consequence is on the rise, with a 19.4 per cent increase in limb amputations during 2014-2017 compared to 2010-2013. At Deep Tech EU, the largest showcase of technologies born out of European Flagships, Grapheal, a spin-off from CNRS-Grenoble (France) will demonstrate how its wound monitoring technology will change the way the healthcare industry deals with the chronic wound epidemic. Connected to a smartphone, Grapheal’s wearable patch enables continuous monitoring of wounds, to empower caregivers and wound sufferers with a smart and accurate assessment tool. The wound patch measures and stores the bio parameters of the wound and communicates this data to the cloud via a smartphone app. This real-time connectivity ensures nurses and doctors can be alerted to early stages of infection and other complications. Our patented formula uses Graphene-on-polymer, in a non-invasive way, to actively react to any changes to the wound. As an atomically thin material, graphene’s electrode conductivity will change according to any physicochemical change, enabling faster detection of problems for patients. Our patch can adapt to any shape of wound, using Graphene’s thin and flexible properties. In fact, the non-invasive nature of the patch actively stimulates wound healing — and we have led eight preclinical studies to prove its bio stimulation properties.” Vincent Bouchiat, Grapheal CEO To see this new technology in action, visit the Deep Tech EU at Mobile World Congress, where you can view a demonstration of this device, alongside other Graphene Flagship breakthrough products. Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More